News Conference News AHA 2025 Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN Michael O'Riordan November 08, 2025
News Conference News EuroPCR 2025 Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI Michael O'Riordan May 21, 2025
News Conference News ACC 2025 RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI Michael O'Riordan April 02, 2025
News Conference News ACC 2025 Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection Michael O'Riordan March 30, 2025
News Conference News ISC 2024 ‘Landmark Moment’ for Middle Meningeal Artery Embolization for Subdural Hematoma Todd Neale February 16, 2024
News Conference News LINC 2023 Good Real-World Outcomes Seen With Next-Generation Carotid Stent L.A. McKeown June 06, 2023
News Conference News ESOC 2023 ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy Todd Neale May 25, 2023
News Conference News TCT 2022 New Faces, New Formats, New Tech: What to Expect From TCT 2022 Shelley Wood September 07, 2022
News Conference News TVT 2022 No Stroke Reduction With Embolic Protection in TAVI, Two Studies Suggest Michael O'Riordan June 09, 2022
News Conference News TCT 2020 Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19 Michael O'Riordan October 14, 2020
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Conference News TVT 2017 Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows Michael O'Riordan June 15, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017